How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

The drug Fessler was taking when she suffered the agonizing side effect was semaglutide, a glucagon-like peptide-1 receptor agonist sold under the brand names Ozempic, Wegovy and Rybelsus.

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Skinny jab? Try skinny juice. For centuries, it’s been enjoyed by people in South America — and it’s long been linked to ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Employers, including Express Scripts parent company Cigna, seek to manage GLP-1 costs through programs administered by the ...